La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Net Income (Continuing Operations) : $3.97 Mil (TTM As of Jun. 2022)

View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. La Jolla Pharmaceutical Co's Net Income (Continuing Operations) for the three months ended in Jun. 2022 was $2.46 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2022 was $3.97 Mil.

La Jolla Pharmaceutical Co Net Income (Continuing Operations) Historical Data

The historical data trend for La Jolla Pharmaceutical Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

La Jolla Pharmaceutical Co Net Income (Continuing Operations) Chart

La Jolla Pharmaceutical Co Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-114.80

-199.47

-116.51

-39.42

19.66

La Jolla Pharmaceutical Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Net Income (Continuing Operations)	Get a 7-Day Free Trial															3.73	-2.26	3.77	-	2.46

La Jolla Pharmaceutical Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.97 Mil.

La Jolla Pharmaceutical Co (NAS:LJPC) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

La Jolla Pharmaceutical Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Jones Road, Suite 400, Waltham, MA, USA, 02451

Website

http://www.ljpc.com

La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.

Executives

Larry G. Edwards	director, officer: Chief Executive Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay	director	HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang	director, 10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff	officer: Chief Commercial Officer	4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla	officer: Chief Medical Officer	1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver	officer: Sr. Vice President, Operations	725 NEWPORT STREET, DENVER CO 80220
James Rolke	officer: Chief Scientific Officer	10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh	director, officer: President, CEO & Secretary